Ashford Benjamin is a specialist executive search firm, focusing on legal recruitment and compliance recruitment in Hong Kong and Asia-Pacific, with a global reach...
Our expert advisors have a long history of placing lawyers into high-profile legal jobs in Hong Kong and Asia-Pacific, including private practice jobs and legal counsel jobs
Our team place Head of Compliance jobs and Chief Compliance Officer jobs in Hong Kong and Asia-Pacific, into financial services, and multi-national companies...
Our expert advisors are highly-qualified, experienced professionals who have been recognised as industry leaders in both legal and compliance recruitment...
Ben always takes the time to ensure he has a genuine understanding of our needs and has a very thorough knowledge of our business and culture. Our firm sits in a niche area that many recruiters do not understand, or do not communicate effectively to potential candidates. Ben spends the time to scour the market for the exact skill-set we require, rather than sending us large numbers of irrelevant CVs. Ben has also provided invaluable consultative advice on our growth and is highly communicative – reaching out to us at least once a week with information on the market.
International Law Firm, Hong Kong: Managing Partner, APAC
Download our 2018 Brochure
Hong Kong - Convictions In Less Than A Year After The Significant Controllers Register Law Came Into Force
On 7 January 2019, the Companies Registry published highlights of several prosecution cases regarding the convictions in November 2018 of twelve Hong Kong companies for having failed to keep and maintain their significant controllers registers ("SCR") in accordance with the Companies Ordinance (Cap 622) (the "CO"). All the companies convicted were fined.
Hong Kong - New HKEx Rules Spur Bumper Year In Hong Kong Capital Markets, But Lasting Impact Remains Unclear.
In April 2018, the Hong Kong Stock Exchange’s (HKEx) rule amendments permitting the listing of innovative, high-growth companies with dual-class share structures and pre-revenue biotech companies went into effect. The long-awaited amendments also facilitated the secondary listing in Hong Kong of Chinese companies with an existing listing on another stock exchange.